News | June 16, 2009

SNM, Siemens Present Award to PET Study Showing Practice-Based Research

June 16, 2009 – The study "Does Positron Emission Tomography Imaging in the Surgical Treatment of Colorectal Liver Metastases add any Value?" by Bastiaan Wiering, M.D., won Siemens Award for Excellence in Practice-Based Research at SNM’s 56th Annual Meeting in Toronto.

The purpose of the award is to encourage clinicians and researchers to create studies that demonstrate the economic value of molecular imaging, including nuclear medicine, in the daily patient management process. This is especially important as many emerging applications and techniques are limited in their adoption. Cooperative efforts to encourage research studies hold potential to drive down the overall cost of healthcare by increasing the quality and accuracy of the information gained using these types of imaging techniques and bolsters efforts for generating evidence for increased reimbursement.
 
The award recognizes an investigator for originality, scientific methodology and practical applications. Submitted abstracts needed to contain scientific examination on the economic value of practice- or evidence-based research in the field of Nuclear Medicine and Molecular Imaging and Therapy.
 
“A key initiative for SNM has been to evaluate the effectiveness of PET-CT and other molecular imaging tests,” said Robert W. Atcher, Ph.D., M.B.A., 2008-09 president of SNM. “The body of research clearly shows that molecular imaging procedures can lead to better detection, earlier diagnosis and improved understanding of the best way to tailor treatments for individual patients. One of the most exciting aspects of this award is that it will allow researchers to directly study the benefits of molecular imaging for improving patient care.”
 
The winners of the 2009 Siemens Award for Excellence in Practice-Based Research are:
First Place: Bastiaan Wiering, MD; Does Positron Emission Tomography Imaging in the Surgical Treatment of Colorectal Liver Metastases add any Value?
Second Place: Mehrbod Javadi, MD; Relationship Between Plaque Burden, Coronary Flow Reserve and Cardiac Events in Hybrid 82Rb PET-CT
Third Place: Lisa Dunnwald, CNMT; PET tumor metabolism in locally advanced breast cancer patients: predicting outcome after neoadjuvant chemotherapy by kinetic analysis of FDG PET
Honorable Mention:
Ronny Buechel, MD; Low-dose and Fast Hybrid Cardiac Imaging: New Method Combining CT Coronary Angiography and SPECT
Ken Herrmann, MD; Cost-effectiveness of Anatometabolic Imaging with PET/CT for Staging of NSCLC
Tomohiro Kaneta, MD, PhD; Dementia Clinical Trials with Longitudinal FDG PET: Improved Statistical Power Using Intra-subject Registration  
Jeong Won Lee, MD; Prediction of Tumor Recurrence by 18F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma
 
“Siemens is honored to work with the SNM since the inception of this award in 2007 to recognize researchers and their tireless work to demonstrate the economical benefits of molecular imaging procedures. As innovation within our industry continues, we need to revisit the efficacy of today’s imaging protocols to diagnose and manage disease and consider revising them to include imaging studies that provide more information. The type of studies that are encouraged by this award will help clinicians as they determine the best treatment paths for their patients,” said Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Healthcare. “This research can also help bolster evidence needed to convince legislators and payers to increase R&D funding and reimbursement of molecular imaging.”
 
To be considered for the award, the papers needed to contain research objectives and/or results that evaluate the potential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) and other molecular imaging-based technology, including:
- reducing costs for payers while increasing or maintaining quality of patient care
- limiting costs for lengthy non-effective treatments
utilizing hybrid devices in a true dual modality use (e.g., PET-CT versus stand-alone CT)
- better utilization of resources (real-estate, operators, etc)
- case-based studies that may be used to address issues related to reductions in reimbursements (e.g., DRA-related reductions)
 
The Siemens Award for Excellence in Practice-Based Research is an SNM initiative with Siemens acting as the official grantor. SNM intends to seek, evaluate, publish and present to an international audience, innovative practice-based investigations concerning the economic pressures and potential business solutions explored via scientific research.
 
The SNM Scientific Program Committee was responsible for evaluating the content of submitted abstracts to determine their eligibility for this award, and consequently selected the winning presentations. A committee selected the key papers, and identified the award winners after the oral presentations were made.
 
For more information: www.siemens.com/healthcare.
 

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
Overlay Init